A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer
| Autor: | Amirhossein Sahebkar, Behzad Behnam, Hossein M. Orafai, Amir Hossein Mohammadzadeh, Tannaz Jamialahmadi, Yunes Panahi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Chemotherapy Bevacizumab business.industry medicine.medical_treatment Ipilimumab medicine.disease Clinical trial 03 medical and health sciences Figitumumab chemistry.chemical_compound 0302 clinical medicine chemistry Atezolizumab Internal medicine Ficlatuzumab medicine 030212 general & internal medicine Lung cancer business medicine.drug |
| Zdroj: | Advances in Experimental Medicine and Biology ISBN: 9783030550349 |
| DOI: | 10.1007/978-3-030-55035-6_3 |
| Popis: | Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer worldwide. It metastasizes rapidly and has a poor prognosis. The first-line treatment for most patients is a combination of chemotherapy and radiation. In many subjects, using targeted treatments alongside chemoradiation has shown a better outcome in terms of progression and quality of life for patients. These targeted treatments include small biological inhibiting molecules and monoclonal antibodies. In this review, we have assessed studies focused upon the treatment of non-small cell lung cancer. Some therapies are approved, such as bevacizumab and atezolizumab, while some are still in clinical trials, such as ficlatuzumab and ipilimumab, and others have been rejected due to inadequate disease control, such as figitumumab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|